Beigene Stock Performance
| ONC Stock | 303.81 0.91 0.30% |
The firm shows a Beta (market volatility) of 1.25, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BeiGene will likely underperform. At this point, BeiGene has a negative expected return of -0.17%. Please make sure to confirm BeiGene's kurtosis, and the relationship between the maximum drawdown and day median price , to decide if BeiGene performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days BeiGene has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.30) | Five Day Return (2.39) | Ten Year Return 972.78 | All Time Return 972.78 |
1 | Disposition of 3848 shares by Chan Lee of BeiGene, at 12.23 subject to Rule 16b-3 | 10/22/2025 |
2 | BeiGene Q3 2025 Earnings Preview | 11/05/2025 |
3 | Disposition of 400 shares by John Oyler of BeiGene, at 327.78 subject to Rule 16b-3 | 11/24/2025 |
4 | Pinpoint Asset Management Singapore Pte. Ltd. Purchases New Stake in BeOne Medicines Ltd. Sponsored ADR ONC | 11/26/2025 |
5 | Will FDA Priority Review for Sonrotoclax Transform BeOne Medicines Strategic Narrative | 12/02/2025 |
6 | BeOne Medicines Valuation Check After FDA Priority Review for Sonrotoclax in Mantle Cell Lymphoma | 12/04/2025 |
7 | 2026 Regulatory Crossfire New Outlook Survey Reveals Health IT Rules Reshaping U.S. Care Delivery | 12/09/2025 |
8 | Disposition of 332 shares by Chan Lee of BeiGene, at 318.28 subject to Rule 16b-3 | 12/10/2025 |
9 | Disposition of 332 shares by Chan Lee of BeiGene, at 325.0 subject to Rule 16b-3 | 12/11/2025 |
10 | Disposition of tradable shares by John Oyler of BeiGene, at 305.24 subject to Rule 16b-3 | 12/16/2025 |
11 | The Bull Case For BeOne Medicines Could Change Following Strong Sonrotoclax BCell Cancer Data - Learn Why | 12/18/2025 |
| Begin Period Cash Flow | 3.2 B | |
| Total Cashflows From Investing Activities | -548.4 M |
BeiGene Relative Risk vs. Return Landscape
If you would invest 34,453 in BeiGene on October 4, 2025 and sell it today you would lose (4,072) from holding BeiGene or give up 11.82% of portfolio value over 90 days. BeiGene is generating negative expected returns assuming volatility of 2.3689% on return distribution over 90 days investment horizon. In other words, 21% of stocks are less volatile than BeiGene, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
BeiGene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BeiGene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BeiGene, and traders can use it to determine the average amount a BeiGene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0727
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ONC |
Based on monthly moving average BeiGene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BeiGene by adding BeiGene to a well-diversified portfolio.
BeiGene Fundamentals Growth
BeiGene Stock prices reflect investors' perceptions of the future prospects and financial health of BeiGene, and BeiGene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BeiGene Stock performance.
| Return On Equity | 0.0181 | ||||
| Return On Asset | 0.0169 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 31.96 B | ||||
| Shares Outstanding | 101.81 M | ||||
| Price To Book | 8.14 X | ||||
| Price To Sales | 6.76 X | ||||
| Revenue | 3.81 B | ||||
| Gross Profit | 4.29 B | ||||
| EBITDA | (396.44 M) | ||||
| Net Income | (644.79 M) | ||||
| Total Debt | 1.08 B | ||||
| Book Value Per Share | 37.33 X | ||||
| Cash Flow From Operations | (140.63 M) | ||||
| Earnings Per Share | 0.52 X | ||||
| Market Capitalization | 33.62 B | ||||
| Total Asset | 5.92 B | ||||
| Retained Earnings | (8.61 B) | ||||
| Working Capital | 1.78 B | ||||
About BeiGene Performance
By analyzing BeiGene's fundamental ratios, stakeholders can gain valuable insights into BeiGene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BeiGene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BeiGene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 273.70 | 165.79 | |
| Return On Tangible Assets | (0.10) | (0.11) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about BeiGene performance evaluation
Checking the ongoing alerts about BeiGene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BeiGene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BeiGene generated a negative expected return over the last 90 days | |
| BeiGene was previously known as BGNE Old and was traded on NASDAQ Exchange under the symbol BGNE. | |
| The company reported the last year's revenue of 3.81 B. Reported Net Loss for the year was (644.79 M) with profit before taxes, overhead, and interest of 4.29 B. | |
| BeiGene generates negative cash flow from operations | |
| BeiGene has a poor financial position based on the latest SEC disclosures | |
| About 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from simplywall.st: The Bull Case For BeOne Medicines Could Change Following Strong Sonrotoclax BCell Cancer Data - Learn Why |
- Analyzing BeiGene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BeiGene's stock is overvalued or undervalued compared to its peers.
- Examining BeiGene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BeiGene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BeiGene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BeiGene's stock. These opinions can provide insight into BeiGene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |